Conjunctival hemorrhagic events associated with imatinib mesylate.
Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. It is well tolerated and leads to no higher incidence of hemorrhagic events than other therapies. Of 87 patients we treated with IM for a minimum of 3 months, 10 patients (11%) developed unilateral or bilateral conjunctival hemorrhage (CH). No other hemorrhagic events were observed during follow-up, except for CH recurrence in 6 cases (7%). Because there was no other obvious reason for such a high incidence of CH, we hypothesize drug hypersensitivity or ocular irritation induced by IM treatment.
Radaelli
Franca
F
Ematologia II-Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via Francesco Sforza 35, Milan, Italy.
Vener
Claudia
C
Ripamonti
Francesco
F
Iurlo
Alessandra
A
Colombi
Mariangela
M
Artoni
Andrea
A
Reda
Gianluigi
G
Deliliers
Giorgio Lambertenghi
GL
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D003229:Conjunctival Diseases / Q000139:chemically induced* / Q000473:pathology; D004342:Drug Hypersensitivity / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy / Q000473:pathology; D006470:Hemorrhage / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate